Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1983 Jan;39(1):247–252. doi: 10.1128/iai.39.1.247-252.1983

Safety and immunogenicity of a group 29E meningococcal capsular polysaccharide vaccine in adults.

J M Griffiss, B L Brandt, P L Altieri, G B Pier, S L Berman
PMCID: PMC347933  PMID: 6401693

Abstract

A serogroup 29E Neisseria meningitidis capsular polysaccharide vaccine at a dose of 50 micrograms was injected subcutaneously into 10 adult human volunteers. One vaccinate experienced a mild systemic reaction; one complained of moderate to severe local pain and tenderness. The vaccine induced significant homologous binding and bactericidal antibody by 2 weeks and significant binding antibody against the heterologous serogroup Z capsular polysaccharide by 4 weeks. Although binding antibody rose during the first 4 weeks and then declined slowly over the subsequent 4 months, bactericidal antibody response declined substantially by 4 and 8 weeks for both polysaccharides. The increase in group 29E bactericidal activity was no longer significant at 4 and 8 weeks; loss of bactericidal activity against group Z was significant by 8 weeks. Bactericidal activity again rose between 8 and 26 weeks, becoming significantly increased over prevaccination levels for group 29E and increased, though not significantly (P = 0.085), over prevaccination levels for group Z. As a result of the failure of induced antibody to increase bactericidal activity, only 40% of vaccinates achieved a greater than 2 log2 increase in lytic activity against group 29E, and none achieved this large an increase in lytic activity against group Z.

Full text

PDF
247

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970 Feb 19;282(8):417–420. doi: 10.1056/NEJM197002192820803. [DOI] [PubMed] [Google Scholar]
  2. Bhattacharjee A. K., Jennings H. J., Kenny C. P. Structural elucidation of the 3-deoxy-D-manno-octulosonic acid containing meningococcal 29-e capsular polysaccharide antigen using carbon-13 nuclear magnetic resonance. Biochemistry. 1978 Feb 21;17(4):645–651. doi: 10.1021/bi00597a013. [DOI] [PubMed] [Google Scholar]
  3. Brandt B. L., Artenstein M. S., Smith C. D. Antibody responses to meningococcal polysaccharide vaccines. Infect Immun. 1973 Oct;8(4):590–596. doi: 10.1128/iai.8.4.590-596.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brandt B. L., Smith C. D., Artenstein M. S. Immunogenicity of serogroup A and C Neisseria meningitidis polysaccharide vaccines administered together in humans. J Infect Dis. 1978 Feb;137(2):202–205. doi: 10.1093/infdis/137.2.202. [DOI] [PubMed] [Google Scholar]
  5. Counts G. W., Petersdorf R. G. 'The wheel within a wheel': meningococcal trends. JAMA. 1980 Nov 14;244(19):2200–2201. [PubMed] [Google Scholar]
  6. Evans J. R., Artenstein M. S., Hunter D. H. Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol. 1968 May;87(3):643–646. doi: 10.1093/oxfordjournals.aje.a120854. [DOI] [PubMed] [Google Scholar]
  7. Gotschlich E. C., Rey M., Etienne J., Sanborn W. R., Triau R., Cvjetanović B. The immunological responses observed in field studies in Africa with group A meningococcal vaccines. Prog Immunobiol Stand. 1971;5:485–491. [PubMed] [Google Scholar]
  8. Griffiss J. M. Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera. J Immunol. 1975 Jun;114(6):1779–1784. [PubMed] [Google Scholar]
  9. Griffiss J. M., Bertram M. A. Immunoepidemiology of meningococcal disease in military recruits. II. Blocking of serum bactericidal activity by circulating IgA early in the course of invasive disease. J Infect Dis. 1977 Dec;136(6):733–739. doi: 10.1093/infdis/136.6.733. [DOI] [PubMed] [Google Scholar]
  10. Griffiss J. M., Brandt B. L., Altieri P. L., Pier G. B., Berman S. L. Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults. Infect Immun. 1981 Dec;34(3):725–732. doi: 10.1128/iai.34.3.725-732.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Griffiss J. M., Brandt B. L., Broud D. D. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun. 1982 Jul;37(1):205–208. doi: 10.1128/iai.37.1.205-208.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Griffiss J. M. Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model. Rev Infect Dis. 1982 Jan-Feb;4(1):159–172. doi: 10.1093/clinids/4.1.159. [DOI] [PubMed] [Google Scholar]
  13. Griffiss J. M. Serum IgA: modulation of complement activation and induction of susceptibility to bacterial dissemination. Infection. 1982;10(4):246–251. doi: 10.1007/BF01666922. [DOI] [PubMed] [Google Scholar]
  14. Käyhty H., Jousimies-Somer H., Peltola H., Mäketä P. H. Antibody response to capsular polysaccharides of groups A and C neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease. J Infect Dis. 1981 Jan;143(1):32–41. doi: 10.1093/infdis/143.1.32. [DOI] [PubMed] [Google Scholar]
  15. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  16. Lowell G. H., Smith L. F., Griffiss J. M., Brandt B. L., MacDermott R. P. Antibody-dependent mononuclear cell-mediated antimeningococcal activity. Comparison of the effects of convalescent and postimmunization immunoglobulins G, M, and A. J Clin Invest. 1980 Aug;66(2):260–267. doi: 10.1172/JCI109852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mäkelä P. H., Käyhty H., Weckström P., Sivonen A., Renkonen O. V. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet. 1975 Nov 8;2(7941):883–886. doi: 10.1016/s0140-6736(75)92125-x. [DOI] [PubMed] [Google Scholar]
  18. OSBORN M. J. STUDIES ON THE GRAM-NEGATIVE CELL WALL. I. EVIDENCE FOR THE ROLE OF 2-KETO- 3-DEOXYOCTONATE IN THE LIPOPOLYSACCHARIDE OF SALMONELLA TYPHIMURIUM. Proc Natl Acad Sci U S A. 1963 Sep;50:499–506. doi: 10.1073/pnas.50.3.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Peltola H., Mäkelä H., Käyhty H., Jousimies H., Herva E., Hällström K., Sivonen A., Renkonen O. V., Pettay O., Karanko V. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977 Sep 29;297(13):686–691. doi: 10.1056/NEJM197709292971302. [DOI] [PubMed] [Google Scholar]
  20. Peltola H., Mäkelä P. H., ELO O., Pettay O., Renkonen O. V., Sivonen A. Vaccination against meningococcal group A disease in Finland 1974-75. Scand J Infect Dis. 1976;8(3):169–174. doi: 10.3109/inf.1976.8.issue-3.09. [DOI] [PubMed] [Google Scholar]
  21. Pier G. B., Sidberry H. F., Zolyomi S., Sadoff J. C. Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa. Infect Immun. 1978 Dec;22(3):908–918. doi: 10.1128/iai.22.3.908-918.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ryan N. J., Hogan G. R. Severe meningococcal disease caused by serogroups X and Z. Am J Dis Child. 1980 Dec;134(12):1173–1173. doi: 10.1001/archpedi.1980.02130240053016. [DOI] [PubMed] [Google Scholar]
  23. Vann W. F., Jann K. Structure and serological specificity of the K13-antigenic polysaccharide (K13 antigen) of urinary tract-infective Escherichia coli. Infect Immun. 1979 Jul;25(1):85–92. doi: 10.1128/iai.25.1.85-92.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wong K. H., Barrera O., Sutton A., May J., Hochstein D. H., Robbins J. D., Robbins J. B., Parkman P. D., Seligmann E. B., Jr Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand. 1977;5(3):197–215. doi: 10.1016/s0092-1157(77)80005-x. [DOI] [PubMed] [Google Scholar]
  25. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979 May;63(5):836–848. doi: 10.1172/JCI109383. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES